E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to Severe Plaque Type Psoriasis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037153 |
E.1.2 | Term | Psoriasis |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to demonstrate that Super-Responders maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (100 mg q16w). |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to evaluate • whether subjects with short disease duration (≤2 years) show a more rapid and better guselkumab response compared to subjects with longer disease duration and whether subjects with shorter disease are more likely to maintain drug-free control of disease after guselkumab withdrawal. To be evaluated in Study Parts 1, 2 and 3. • whether SRe with short disease duration and PASI=0 at week 116 will show sustained remission (ie, PASI=0) over two additional years compared to subjects with longer disease duration. To be evaluated in Study Part 3. • whether SRe with short disease duration and PASI>0 to ≤5 at week 116 will show continued loss of response or stabilization of disease worsening over two additional years compared to subjects with longer disease duration. To be evaluated in Study Part 3.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Substudies (part of the final protocol dated 05-Jul-2018): Four substudies are planned to further evaluate pharmacologic effects of guselkumab and evaluate various pharmacologic/clinical response relationships allowing assessment of inter-individual variability in clinical outcomes and possible identification of subject population groups that may respond differently to guselkumab. The substudies will also aim to further define the mechanism of action (MoA) of guselkumab at the molecular and cellular levels during and after treatment. Changes in gene expression as well as quantitative and qualitative changes in different types of immune cells will be evaluated in skin biopsies and blood.
- Substudy 1 (Cellular MoA substudy) - Substudy 2 (Gene expression substudy) - Substudy 3 (Serum analysis) - Substudy 4 (Genetic analyses)
Exploratory objectives The following objectives are to be explored in the mechanistic biomarker substudies: • characterization of the immune cellular and molecular composition at baseline (week 0) and changes in the lesional skin of subjects during treatment with guselkumab as determined by fluorescence activated cell sorting (FACS)-based analysis. To be explored in substudy 1 • characterization of the immune cellular changes in the blood of subjects at baseline (week 0), during and after treatment with guselkumab as determined by FACS-based analysis. To be explored in substudy 1 • characterization of molecular (gene expression) changes during treatment with guselkumab in the skin of subjects treated with guselkumab as determined by RNA sequencing (RNAseq) and quantitative polymerase chain reaction (qPCR). To be explored in substudy 2 and 3 • characterization of the tissue immunopathological changes in the skin of subjects during and after treatment with guselkumab as determined by immunohistochemistry (IHC)/ immunofluorescence (IF)/ in situ hybridization (ISH). To be explored in substudy 2 • characterization of the effects of guselkumab treatment on serum biomarkers as determined by immunoassays. To be explored in substudy 3 • characterization of the association between changes in the various exploratory biomarker endpoints and 1) efficacy of guselkumab, 2) duration of psoriasis, 3) maintenance of response after stopping guselkumab treatment, and 4) ability to achieve a PASI 100 response at weeks 20 and 28 (super responder status). To be explored in all substudies |
|
E.3 | Principal inclusion criteria |
1. Male or female with at least 18 years of age. 2. Has a disease duration of plaque psoriasis of either ≤2 years or >2 years calculated from date at which first symptoms [plaque] were reported by subject to date of screening visit at screening; approximately 40% subjects must have a disease duration ≤2 years. 3. Has moderate-to-severe plaque-psoriasis defined by a PASI score >10 or affected BSA >10% and additionally a DLQI score >10 at baseline (week 0). 4. Is a candidate for systemic treatment for psoriasis. 5. Before first administration of study drug, a woman must be: a. Not of childbearing potential b. Of childbearing potential and practicing a highly effective method of contraception
For the complete overview of the inclusion criteria, please refer to section 4.1 of the protocol |
|
E.4 | Principal exclusion criteria |
1 clinical active psoriasis arthritis which needs systemic therapy beyond NSAIDs 2 diagnosed or reported history or current signs or symptoms indicating severe, progressive, or uncontrolled hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, which are detected at screening assessments 3 unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months, diagnosed or reported by the subject 4 Has a transplanted organ 5 history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced
For the complete overview of the exclusion criteria, please refer to section 4.2 of the protocol
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the main study is the proportion of subjects in study groups 2a and 2b who achieve an absolute PASI score <3 at week 68. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Major secondary endpoints of this study are: • Time to improvement from baseline (week 0) in PASI (PASI 75/90/100 response and absolute PASI score = 0) for subjects with short (≤ 2 years) and longer (>2 years) disease duration per study group (1, 2a 2b, and 2c) • Proportion of subjects with short (≤2 years) and longer (>2 years) disease duration who achieve an absolute PASI score of 0, ≤1 and <3 at weeks 20, 28, 68, 116, 164 and 220 per study group (1, 2a, 2b, 2c, 3a and 3b) • Proportion of subjects who retain disease control (ie, absolute PASI score <3 at all visits) from week 68 through week 116, from week 68 through week 164, and from week 68 through week 220 for subjects with short (≤ 2 years) and longer (>2 years) disease duration per study group (3a and 3b). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Weeks 12, 16, 20, 28, 36, 52, 68, 116, 164 and 220 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 90 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 100 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |